Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Durvalumab Combinations in Resectable NSCLC
NCT03794544Phase 2Completed
- Sponsor
- MedImmune
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Modified DNA Oligonucleotides
- Countries
- 7
01
Overview
A Phase 2 trial of durvalumab, oleclumab, monalizumab, danvatirsen in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Mar 2019; status: completed.
02
Drugs
durvalumaboleclumabmonalizumabdanvatirsen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03794544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794544.